Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 14/20 | 0.46 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.37 |
| ▸ | CTSD | P07339 | 2/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.30 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL933512 | 0.84 | BACE1 (0.63) | BACE1NPY5RCTSDKCNH2 | |
| SCHEMBL932350 | 0.83 | BACE1 (0.50) | BACE1CTSDKCNH2 | |
| SCHEMBL932551 | 0.83 | BACE1 (0.40) | BACE1CTSDKCNH2 | |
| SCHEMBL932646 | 0.81 | BACE1 (0.46) | BACE1NPY5RCTSDKCNH2MEN1 | |
| SCHEMBL932676 | 0.79 | MAPT (0.38) | BACE1CTSDMEN1KMT2AMAOB | |
| SCHEMBL933481 | 0.77 | BACE1 (0.39) | BACE1CTSDKCNH2HCAR3HCAR2 | |
| SCHEMBL932682 | 0.76 | BACE1 (0.53) | BACE1CTSDKCNH2MAOB | |
| SCHEMBL932046 | 0.71 | BACE1 (0.60) | BACE1CTSDKCNH2 | |
| SCHEMBL932108 | 0.69 | BACE1 (0.62) | BACE1CTSDKCNH2 | |
| SCHEMBL932706 | 0.68 | BACE1 (0.66) | BACE1CTSDKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011002407-A1 | NOVEL COMPOUNDS FOR TREATMENT OF NEURODEGENERATION ASSOCIATED WITH DISEASES, SUCH AS ALZHEIMER'S DISEASE OR DEMENTIA | ASTRAZENECA AB (SE) | 2011-01-06 | — | — | WO | disclosed |
| WO-2011002407-A1 | NOVEL COMPOUNDS FOR TREATMENT OF NEURODEGENERATION ASSOCIATED WITH DISEASES, SUCH AS ALZHEIMER'S DISEASE OR DEMENTIA | ASTRAZENECA AB (SE) | 2011-01-06 | — | — | WO | disclosed |